share_log

研报掘金丨开源证券:人福医药三个产品首次纳入医保,维持“买入”评级

Research reports spotlight | Open Source Securities: Three products of humanwell healthcare included in medical insurance for the first time, maintaining a "buy" rating

Gelonghui Finance ·  Dec 2 01:57  · Ratings

Grain Hunting on December 2nd | Open Source Securities research reports pointed out that humanwell healthcare (600079.SH) three products were first included in medical insurance, expected to contribute new performance quantities, maintaining a "buy" rating. In November 2024, Yichang humanwell injected Propofol sodium, Hydrocodone hydrochloride sustained-release tablets, and Chloramphenicol tablets were first included in the medical insurance catalog. The inclusion of these three products in medical insurance will continue to increase the market accessibility and sales potential of pharmaceuticals, further diversifying the company's profit growth points. Through continuous innovation and high-quality production, the company is expected to continue to expand its market share and enhance its competitive position in the pharmaceutical industry. The inclusion of the company's products in medical insurance this time once again increases the company's profit growth points, and anesthesia products are expected to quickly increase production. With the steady progress of shareholders' restructuring, the leading anesthetic is expected to usher in a valuation repair.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment